| Literature DB >> 36147188 |
Haviv Muris Saputra1,2, Furqan Hidayatullah1,2, Yudhistira Pradnyan Kloping1,2, Johan Renaldo1,2, Eric Chung3, Lukman Hakim1,4.
Abstract
Background: Penile cancer is rare among male malignancies. Various biomarkers have been used to predict the prognosis of cancer, one of which is the neutrophil to lymphocyte ratio (NLR). Therefore, we conducted this systematic review and meta-analysis to evaluate the prognostic value of NLR in penile cancer.Entities:
Keywords: Cancer; Cancer-specific survival; Neutrophil to lymphocyte ratio; Overall survival; Penile cancer
Year: 2022 PMID: 36147188 PMCID: PMC9486611 DOI: 10.1016/j.amsu.2022.104335
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Keywords used as literature search strategy.
| Search-engine | Keywords | Article(n) |
|---|---|---|
| PubMED | (“neutrophil-to-lymphocyte ratio"[All Fields] OR “neutrophil-to-lymphocyte ratio"[All Fields] OR “nlr"[All Fields]) AND (((“penil"[All Fields] OR “penis"[MeSH Terms] OR “penis"[All Fields] OR “penile"[All Fields]) AND (“carcinoma"[MeSH Terms] OR “carcinoma"[All Fields] OR “carcinomas"[All Fields] OR “carcinoma s"[All Fields])) OR (“penile neoplasms"[MeSH Terms] OR (“penile"[All Fields] AND “neoplasms"[All Fields]) OR “penile neoplasms"[All Fields] OR (“penile"[All Fields] AND “cancer"[All Fields]) OR “penile cancer"[All Fields]) OR (“penile neoplasms"[MeSH Terms] OR (“penile"[All Fields] AND “neoplasms"[All Fields]) OR “penile neoplasms"[All Fields] OR (“penis"[All Fields] AND “neoplasms"[All Fields]) OR “penis neoplasms"[All Fields])) | 12 |
| Scopus | TITLE-ABS-KEY ((“neutrophil two lymphocyte ratio” OR “neutrophil-two-lymphocyte ratio” OR nlr) AND (penile AND carcinoma OR penile AND cancer OR penis AND neoplasms)) | 18 |
| Science-direct | (“neutrophil to lymphocyte ratio” OR “neutrophil-to-lymphocyte ratio” OR nlr) AND (penile carcinoma OR penile cancer OR Penis neoplasms) | 92 |
| 122 |
Fig. 1Systematic Search and Screening based on the 2020 PRISMA flow diagram.
Baseline characteristics of the included study.
| No | Author & years of publication | Years of Data Collection | Patient's TNM Staging | Country | Study Design | Total patients (n) | Group Allocation | Allocated patients (n) | Cancer Pathology | Age in years (mean ± SD) | Follow-up duration |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kasuga et al., 2016 | 1999–2015 | T1, T2, T3, T4 N0, N + M0, M+ | Japan | Single Institutional Retrospective Cohort | 41 | High NLR | 20 | Penile SCC | 68.5 ± 11.4 | 34.7 (2.3–271.7) months |
| Low NLR | 21 | ||||||||||
| 2 | Tan et al., 2017 | 2007–2015 | Ta, T1a, T1b, T2, T3 | Singapore | Single Institutional Retrospective Cohort | 39 | High NLR | NR | Penile SCC | 65. (59–72.5) | 34 (16.5–66) months |
| N0, N1, N2, N3 | Low NLR | NR | |||||||||
| 3 | Azizi et al., 2018 | 1994–2014 | Tx, Tis/Ta/T1a, T1b, T2, T3, T4 | USA | Single Institutional Retrospective Cohort | 84 | High NLR | 38 | Penile SCC | 63.6(54–68.7) | 35.5 (19.4–89.6) months |
| N0, N+ | Low NLR | 30 | |||||||||
| 4 | Li et al., 2019 | 2002–2015 | ≤T1, ≥T2 | China | Multi- Institutional Retrospective cohort | 228 | High NLR | 105 | Penile SCC | 52(24–85) | 25 (1–140) months |
| N0, N+ | Low NLR | 123 | |||||||||
| 5 | Jiao Hu et al., 2020 | 2010–2018 | Tis, Ta/T1a, ≥T1b | China | Single Institutional Retrospective Cohort | 134 | High NLR | 32 | Penile SCC | 54.95 ± 10.6 | 32.1(2–94) month |
| No, N+ | Low NLR | 47 | |||||||||
| 6 | Chen Hu et al., 2020 | 2002–2017 | T0, T1, T2, T3, T4 | China | Single Institutional Retrospective Cohort | 225 | High NLR | 68 | Penile SCC | 50.6 ± 13.4 | 30 (16–63.5) months |
| N0, N1, N2, N3 M0, M1 | Low NLR | 157 | |||||||||
| 7 | Jindal et al., 2021 | 2012–2020 | T1, T2, T3, T4 | India | Single Institutional Retrospective Cohort | 69 | High NLR | 40 | Penile SCC | NR | 18 (2–74) months |
| N0, N1, N2, N3 | Low NLR | 29 |
Data expressed as median and range.
Data expressed as median and interquartile (IQR) range, SCC = Squamous cell carcinoma.
Outcome assessment and treatment received in the included studies.
| No | Author & years of publication | Surgical Intervention | NLR (mean ± SD) | NLR Cut-off | Cut-off point calculation | Median OS | Median CSS | Primary Outcome | Secondary Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kasuga et al., 2016 | Radical Penectomy | 5.03 ± 4.99 | 2.82 | AUC | NR | NR | OS, CSS | LNM |
| 2 | Tan et al., 2017 | Bilateral modified inguinal lymph node dissection or dynamic sentinel node biopsy | 2.99 (0.76–5.22) | 2.8 | AUC | NR | NR | CSS, PFS, | LNM |
| 3 | Azizi et al., 2018 | Bilateral/unilateral inguinal lymph node dissection | 4.51 ± 3.95 | 3 | Contal and O'Quigley method | 89 (31.2–123.6) months | NR | OS, CSS, RFS | LNM |
| 4 | Li et al., 2019 | Bilateral inguinal lymph node dissection | 2.4 (0.1–44.2) | 2.6 | ROC | NR | NR | CSS | LNM |
| 5 | Jiao Hu et al., 2020 | Bilateral inguinal lymph node dissection after primary tumor procedure | NR | 3.59 | ROC | NR | NR | CSS | LNM |
| 6 | Chen Hu et al., 2020 | Inguinal lymph node dissection | NR | 2.94 | AUC | 34 (18–84) months | 33 (18–85.25) months | OS, PFS | LNM |
| 7 | Jindal et al., 2021 | Penectomy with bilateral inguinal node dissection | NR | 3 | Following previous study by Azizi et al. | NR | 18 (2–74) months | CSS | LNM |
NLR = Neutrophil-lymphocyte ratio, ROC = Receiver operating characteristic curve, AUC = Area under the curve, OS = Overall Survival, CSS = Cancer specific-survival, PFS = Progression-free survival, LNM = Lymph-Node Metastasis.
Data expressed as median and range.
Data expressed as median and interquartile (IQR) range.
Oncological outcomes results summary for penile SCC with high NLR compared to low NLR.
| Outcome | Analysis methods | Reference | Result | |
|---|---|---|---|---|
| Overall Survival | Univariate Analysis | Kasuga et al., 2016 | NR | 0.076 |
| Chen Hu et al., 2020 | HR: 2.97 (95% CI 1.74 to 5.06) | <0.001 | ||
| Multivariate Analysis | Chen Hu et al., 2020 | HR: 1.28 (95% CI 0.61 to 2.72) | 0.516 | |
| Azizi et al., 2018 | HR: 2.48 (95% CI 1.02 to 6.03) | 0.046 | ||
| Cancer-Specific Survival | Univariate Analysis | Kasuga et al., 2016 | NR | 0.023 |
| Azizi et al., 2018 | HR: 6.16 (95% CI 2.1 to 18.07) | 0.014 | ||
| Jiao Hu et al., 2020 | HR: 3.36 (95% CI 1.49 to 7.58) | <0.01 | ||
| Jindal et al., 2021 | NR | 0.05 | ||
| Multivariate Analysis | Tan et al., 2017 | NR | <0.01 | |
| Azizi et al., 2018 | HR: 2.58 (95% CI 0.79 to 8.43) | 0.116 | ||
| Li et al., 2019 | HR: 2.25 (95% CI 1.12 to 4.51) | 0.023 | ||
| Jiao Hu et al., 2020 | HR: 1.27 (95% CI 0.28 to 5.70) | 0.76 | ||
| Jindal et al., 2021 | NR | 0.94 | ||
| Lymph-Node Metastasis | Univariate Analysis | Azizi et al., 2018 | OR: 3.75 (95% CI 1.30 to 10.81) | 0.014 |
| Chen Hu et al., 2020 | OR: 2.21 (95% CI 1.23 to 3.99) | 0.008 | ||
| Jiao Hu et al., 2020 | OR: 6.92 (95% CI 2.46 to 19.43) | <0.01 | ||
| Jindal et al., 2021 | OR: 6.13 (95% CI 2.13 to 17.65) | 0.001 | ||
| Kasuga et al., 2016 | OR: 5.12 (95% CI 0.91 to 28.64) | 0.049 | ||
| Multivariate Analysis | Azizi et al., 2018 | OR: 3.66 (95% CI 0.82 to 16.34) | 0.091 | |
| Jiao Hu et al., 2020 | OR: 10.93 (95% CI 2.81 to 42.51) | <0.01 | ||
| Jindal et al., 2021 | NR | 0.09 |
OR = Odds ratio, HR = Hazard Ratio, NR = Not reported.
Risk of bias assessment using the Newcastle-Ottawa Scale.
| Authors | Selection | Comparability | Outcome | Total Score |
|---|---|---|---|---|
| Tindal et al., 2021 | *** | ** | ** | 7 |
| Hu Jiao et al., 2020 | *** | ** | *** | 8 |
| Zaishang et al., 2020 | **** | ** | *** | 9 |
| Hu Chen et al., 2020 | *** | ** | *** | 8 |
| Azizi et al., 2018 | **** | ** | *** | 9 |
| Kasuga et al., 2016 | *** | ** | *** | 8 |
Fig. 2Forest plot comparison of unadjusted OR of node invasion in penile cancer patients with high NLR versus low NLR.
Fig. 3Forest plot comparison of adjusted OR of lymph node invasion in penile cancer patients with high NLR versus low NLR.
Fig. 4Forest plot comparison of unadjusted HR of CSS in penile cancer patients with high NLR versus low NLR.
Fig. 5Forest plot comparison of adjusted HR of CSS in penile cancer patients with high NLR versus low NLR.
Fig. 6Forest plot comparison of adjusted HR of OS in penile cancer patients with high NLR versus low NLR.